Clinical trials: Helicobacter
Helicobacter Pylori Infection
Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is the most common chronic bacterial infection in humans. The prevalence of H. pylori is about 30~50% in the Western adult population.
- Trial name
- NCT03521726
- Testing
- Amoxicillin, Rabeprazole, Amoxicillin
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Mackay Memorial Hospital
Helicobacter Pylori Infection
Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is the most common chronic bacterial infection in humans. The prevalence of H. pylori is about 30~50% in the Western adult population.
- Trial name
- NCT03524833
- Testing
- Metronidazole, Lansoprazole, Amoxicillin, Metronidazole
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Mackay Memorial Hospital
Helicobacter Pylori Infection, Gastric Ulcer
Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects
The primary objective is to obtain stool samples from post-therapy subjects already undergoing evaluation for an H. pylori infection by upper esophagogastroduodenoscopy (EGD) and gastric biopsy.
- Conditions
- Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain
- Trial name
- NCT03060733
- Testing
- Post-Therapy
- Where
- 5 sites in United States, Italy
- Volunteers
- 13 people
- Sponsor
- DiaSorin Inc.
Helicobacter Pylori Infection
Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy
The Asian-Pacific Consensus Report has recommended that proton pump inhibitor (PPI)-clarithromycin-amoxicillin or metronidazole treatment for 7 to14 days is the first choice treatment for H pylori infection.
- Trial name
- NCT03383003
- Testing
- Nexium, Amolin, Klaricid
- Where
- Taiwan
- Volunteers
- 240 people
- Sponsor
- Chang Gung Memorial Hospital
Helicobacter Pylori Infection, Helicobacter Gastritis
Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication
The hypothesis and plan of the current study are: 1. One induction phase of high dose PPI before eradication will increase intragastric pH and induce H. pylori into an active replicative status.
- Conditions
- Helicobacter Pylori Infection, Helicobacter Gastritis, Helicobacter-Associated Pyloric Ulcer
- Trial name
- NCT03802318
- Testing
- Rabeprazole
- Where
- Taiwan
- Volunteers
- 530 people
- Sponsor
- Chang Gung Memorial Hospital
Helicobacter Pylori
TAK-438 Bismuth Drug Interaction Study
To evaluate the safety, tolerability, and pharmacokinetics (PK) of quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole.
- Trial name
- NCT02892409
- Testing
- Clarithromycin, Amoxicillin, Tripotassium bismuth dicitrate
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Takeda
Helicobacter Pylori Eradication Rate
Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori
Helicobacter pylori (H. pylori) infects more than 50% of the population in the world(1), especially 47-66% in China.
- Trial name
- NCT02776371
- Testing
- Modified non-clarithromycin triple therapy, Sequential therapy
- Where
- China
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Shandong University
Helicobacter Pylori Gastrointestinal Tract Infection
Comparison Efficacy of 14-day Concomitant Therapy:Clarithromycin vs.Levofloxacin in Eradication of H.Pylori
Comparison Efficacy of 14-day Concomitant therapy between levofloxacin and Clarithromycin on the Eradication of Helicobacter Pylori in Syrian population
- Trial name
- NCT03021590
- Testing
- Clarithromycin 500Mg Oral Tablet, Levofloxacin 500Mg Oral Tablet
- Where
- Syria
- Sponsor
- Damascus Hospital
Helicobacter Pylori Infection
A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection
The purpose of this study is to assess efficacy of a new 14-day sequential therapy for the rescue treatment of refractory Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.
- Trial name
- NCT03658733
- Testing
- esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days), rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection
High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment
Dual therapy for Helicobacter Pylori including a proton pump inhibitor (PPI) and amoxicillin. Amoxicillin has low resistance rate as well as low percentage of side effects.
- Trial name
- NCT03405584
- Testing
- Esomeprazole, Amoxicillin, Bismuth Potassium Citrate
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection
Analysis of the Impact of Helicobacter Pylori on Salivary Microbiome in Adults
Helicobacter pylori (H. pylori), a bacteria transmitted from human to human through upper digestive tract as well as fecal-oral transmission, had infected more than half of people around the world. However, the quantity of H.
- Trial name
- NCT03730766
- Testing
- Esomeprazole, Amoxicillin, Bismuth Potassium Citrate
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Gastritis, Helicobacter Pylori Associated Gastritis
Linked Color Imaging to Differentiate H. Pylori Associated Gastritis and Gastric Atrophy
H. pylori infection plays a very important role in gastric carcinogenesis, progressing from chronic gastritis through atrophic gastritis, intestinal metaplasia, dysplasia and finally cancer. It is difficult to diagnose H.
- Conditions
- Gastritis, Helicobacter Pylori Associated Gastritis, Atrophic Gastritis
- Trial name
- NCT02724280
- Testing
- WLE and then LCI, LCI and then WLE
- Where
- China
- Volunteers
- 253 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Helicobacter Pylori Infection
Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication
The investigators aimed to assess the effect of probiotic supplementation with Vigiis 101-LAB during H. pylori eradication therapy with 14-day sequential therapy in the reduction of adverse effects and the restoration of the…
- Trial name
- NCT03722433
- Testing
- Vigiis 101-LAB and sequential therapy
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection
Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the First-line Eradication of H. Pylori
We aimed to (1) compare the efficacy of genotypic resistance guided sequential therapy vs. susceptibility testing guided therapy in the first-line therapy (2) assess the long term impact of eradication therapy on the antibiotic…
- Trial name
- NCT03556254
- Testing
- GGT, SGT
- Where
- Taiwan
- Volunteers
- 560 people
- Sponsor
- National Taiwan University Hospital
Immune Thrombocytopenic Purpura, Helicobacter Pylori
H. Pylori Eradication for Moderate ITP
The purpose of this study is to determine the efficacy of H. pylori eradication for the treatment of chronic or persistent immune thrombocytopenic purpura (ITP) patients with moderate thrombocytopenia.
- Conditions
- Immune Thrombocytopenic Purpura, Helicobacter Pylori, Immune Thrombocytopenia
- Trial name
- NCT03177629
- Testing
- treatment : H. pylori eradication
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Seoul National University Hospital
Helicobacter Pylori Infection
Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy
Doxycycline- and Furazolidone-containing Quadruple Regimen can be a successful rescue treatment for Helicobacter pylori Infection patients after Failure of several therapy.
- Trial name
- NCT02894268
- Testing
- Doxycycline, Furazolidone, Esomeprazole
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sir Run Run Shaw Hospital
Helicobacter Pylori Infection
Impact of Periodontal Treatment on Gastric Helicobacter Pylori Eradication
The efficacy of conventional systemic antibiotic therapy for eradication of gastric H. pylori has been seriously challenged by antibiotic resistance.
- Trial name
- NCT03654781
- Testing
- Triple therapy, professional periodontal treatment
- Volunteers
- 98 people
- Sponsor
- Ondokuz Mayıs University
Helicobacter Pylori Infection
Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment
With markedly increased antibiotic resistance and unsatisfactory efficacies of common empiric eradication regimens in the mainland of China, tailored therapy may be the best choice to achieve good efficacy.
- Trial name
- NCT02935010
- Testing
- Esomeprazole, Bismuth Potassium Citrate, Amoxicillin
- Where
- 5 sites in China
- Volunteers
- 382 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection
Tailored Therapy for Helicobacter Pylori Rescue Treatment
With increasing antibiotic resistance and unsatisfactory results of empiric eradication regimens, tailored therapy may be the best choice to achieve high efficacy for rescue treatment.
- Trial name
- NCT03413020
- Testing
- esomeprazole, bismuth Potassium Citrate, amoxicillin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection
The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection.
Clarithromycin (CLA)、amoxicillin (AMO)、metronidazole (MET)、levofloxacin (LEV) and tetracycline (TET) are commonly used antibiotics for Helicobacter pylori (Hp) therapy.
- Trial name
- NCT03583476
- Testing
- Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole
- Where
- Taiwan
- Volunteers
- 1,821 people
- Sponsor
- National Taiwan University Hospital